Corvus Pharmaceuticals CRVS Operating Lease Liabilities (Current)
Operating Lease Liabilities (Current) at other companies
Other financials
Where this comes from
Reported directly by Corvus Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:OperatingLeaseLiabilityCurrent.
The official record: Corvus Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Corvus Pharmaceuticals's operating lease liabilities (current).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Corvus Pharmaceuticals's operating lease liabilities (current)?
- Corvus Pharmaceuticals (CRVS) reported operating lease liabilities (current) of $428K in Q1 2026.
- How has Corvus Pharmaceuticals's operating lease liabilities (current) changed year-over-year?
- Corvus Pharmaceuticals's operating lease liabilities (current) increased by 34.2% year-over-year, from $319K to $428K.
- What is the long-term trend for Corvus Pharmaceuticals's operating lease liabilities (current)?
- Over 5 years (2020 to 2025), Corvus Pharmaceuticals's operating lease liabilities (current) has grown at a -17.9% compound annual growth rate (CAGR), from $1.08M to $403K.
- What does operating lease liabilities (current) mean?
- The current portion of operating lease obligations due within one year, representing committed future lease payments under ASC 842.